StockMarketWire.com - Mereo BioPharma successfully completed patient enrolment in a Phase 2b dose-confirmation study for the treatment of hypogonadotropic hypogonadism (HH) in men with a body mass index of over 30. BGS-649 is a once a week oral aromatase inhibitor that restores a patient's own testosterone to normal levels by inhibiting the conversion of testosterone to oestradiol. A total of 270 patients have been enrolled into a randomised placebo controlled Phase 2b dose-confirmation study assessing three different dosing regimens. This follows a positive outcome, announced in March 2017, of a blinded interim review of the safety and efficacy of all the three doses based on 93 patients who had received at least one month's treatment. The primary endpoint of this study is to demonstrate the efficacy of BGS-649 to normalise total testosterone levels in over 75% of subjects after 24 weeks of treatment. Secondary endpoints are based on the impact of BGS-649 on luteinising hormone (LH), follicle stimulating hormone (FSH) and semen parameters. In addition the company is exploring patient recorded outcomes including sexual function and fatigue. Top-line data are expected in the first quarter of 2018. Additionally, a six-month extension study in up to 120 patients to confirm the safety of long term treatment with BGS-649 is well underway. Mereo BioPharma Chief Medical Officer Alastair Mackinnon commented: "We are delighted to have completed enrolment in our Phase 2b study for BGS-649, which is another important milestone in the development of the company. "BGS-649 is highly differentiated from current treatment options and those in development, which are based on delivering exogenous testosterone. "We believe that BGS-649 has the potential to be an important new safe, effective and more convenient treatment for the men suffering from this debilitating condition. "We look forward to announcing the top line results of the trial in Q1 2018." Story provided by StockMarketWire.com